Model-informed drug development aims to reduce drug loss in Japan, highlighting collaboration with the pharmaceutical industry and regulators.
ABSTRACT ‘Drug loss’ in Japan refers to drugs that have been approved and marketed overseas but haven't been developed, submitted, or approved in Japan. A comprehensive Model‐Informed Drug Development (MIDD) strategy, enhanced with artificial intelligence/machine learning, can minimize drug loss. Continued pharmaceutical industry and regulatory commitment and collaboration in applying MIDD will facilitate Japanese patients' access to essential medicines and solidify Japan's role in global pharmaceutical advancement.
No takes yet. Share an insight, caveat, or question.
Imai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: